avelumab
merck,pfizer
['prodige 54', 'avelumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
 samco-prodige 54 phs-ii at lb22 avelumab vs chemotherapy in 122 2nd line #crc pts curves crossing, but 12- &amp; 18-month pfs rates 19% vs 9% &amp; 31% vs 27% in favor of avelumab not convincing, we need to understand ici resistance in msi crc 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine